Marco Brugia

632 total citations
31 papers, 354 citations indexed

About

Marco Brugia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Marco Brugia has authored 31 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Marco Brugia's work include Colorectal Cancer Treatments and Studies (8 papers), Gastric Cancer Management and Outcomes (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Marco Brugia is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Gastric Cancer Management and Outcomes (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Marco Brugia collaborates with scholars based in Italy and United States. Marco Brugia's co-authors include Lorenzo Antonuzzo, Serena Pillozzi, Elisa Giommoni, Francesca Mazzoni, Giandomenico Roviello, Enrico Caliman, Franca Castiglione, Enrico Mini, Daniele Lavacchi and Francesco Di Costanzo and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and British Journal of Cancer.

In The Last Decade

Marco Brugia

29 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco Brugia Italy 12 218 128 117 100 32 31 354
Alexander B. Sibley United States 12 171 0.8× 80 0.6× 124 1.1× 71 0.7× 47 1.5× 27 393
Davide Bosso Italy 12 132 0.6× 167 1.3× 133 1.1× 70 0.7× 21 0.7× 18 366
Aurélie Ferru France 11 250 1.1× 82 0.6× 93 0.8× 86 0.9× 84 2.6× 30 439
Nikoletta Sidiropoulos United States 8 163 0.7× 114 0.9× 76 0.6× 135 1.4× 33 1.0× 21 336
In Ae Park South Korea 9 208 1.0× 90 0.7× 92 0.8× 146 1.5× 45 1.4× 11 337
Landon C. Brown United States 12 195 0.9× 252 2.0× 108 0.9× 89 0.9× 28 0.9× 29 372
Khémaies Slimane France 8 282 1.3× 180 1.4× 99 0.8× 237 2.4× 55 1.7× 18 447
Meiling Zhu China 14 137 0.6× 156 1.2× 199 1.7× 92 0.9× 40 1.3× 25 410
Tristan Maurina France 10 108 0.5× 154 1.2× 118 1.0× 73 0.7× 34 1.1× 30 293
Hy-De Lee South Korea 12 228 1.0× 61 0.5× 115 1.0× 157 1.6× 45 1.4× 16 411

Countries citing papers authored by Marco Brugia

Since Specialization
Citations

This map shows the geographic impact of Marco Brugia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Brugia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Brugia more than expected).

Fields of papers citing papers by Marco Brugia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Brugia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Brugia. The network helps show where Marco Brugia may publish in the future.

Co-authorship network of co-authors of Marco Brugia

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Brugia. A scholar is included among the top collaborators of Marco Brugia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Brugia. Marco Brugia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paulet, A. Crastes de, Daniele Lavacchi, Marco Brugia, et al.. (2025). Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift. World Journal of Gastrointestinal Oncology. 17(6). 106707–106707.
2.
Lavacchi, Daniele, Luca Messerini, Vittorio Briganti, et al.. (2024). Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma. Anti-Cancer Drugs. 36(1). 85–88. 1 indexed citations
3.
Lavacchi, Daniele, Fabio Staderini, Marco Brugia, et al.. (2023). TRG-High/ATM-Expressed/SIRT1-Absent Profile as Negative Prognostic Marker after Neoadjuvant Chemotherapy for Gastric Cancer. 8(2). 1 indexed citations
4.
Lavacchi, Daniele, Sara Fancelli, Enrico Caliman, et al.. (2023). Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. International Journal of Molecular Sciences. 24(5). 4877–4877. 11 indexed citations
5.
Giommoni, Elisa, Serena Pillozzi, Enrico Caliman, et al.. (2023). Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.. Journal of Clinical Oncology. 41(16_suppl). e21144–e21144. 1 indexed citations
6.
Catalano, Martina, Daniele Lavacchi, Elisa Giommoni, et al.. (2023). Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI. Future Oncology. 19(38). 2537–2546.
7.
8.
Lavacchi, Daniele, Giandomenico Roviello, Silvia Romano, et al.. (2023). Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. International Journal of Molecular Sciences. 24(6). 5840–5840. 9 indexed citations
9.
Roviello, Giandomenico, Martina Catalano, Luigi Francesco Iannone, et al.. (2022). Current status and future perspectives in HER2 positive advanced gastric cancer. Clinical & Translational Oncology. 24(6). 981–996. 20 indexed citations
10.
Lavacchi, Daniele, Sara Fancelli, Giandomenico Roviello, et al.. (2022). Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer. Frontiers in Oncology. 12. 1055019–1055019. 16 indexed citations
11.
Roviello, Giandomenico, Isacco Desideri, Marco Brugia, et al.. (2021). Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. Endocrine. 74(1). 172–179. 25 indexed citations
12.
Fancelli, Sara, Enrico Caliman, Francesca Mazzoni, et al.. (2021). Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers. 13(5). 1091–1091. 29 indexed citations
13.
Salvianti, Francesca, Stefania Gelmini, Irene Mancini, et al.. (2021). Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. British Journal of Cancer. 125(1). 94–100. 31 indexed citations
14.
Gambale, Elisabetta, Daniele Lavacchi, Marco Brugia, et al.. (2021). Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules. 26(19). 5789–5789. 26 indexed citations
15.
Giommoni, Elisa, Serena Pillozzi, Francesca Mazzoni, et al.. (2020). Somatostatin analogs in pregnant patients with neuroendocrine tumor. Anti-Cancer Drugs. 31(10). 1096–1098. 5 indexed citations
16.
Bartolini, Ilenia, Maria Novella Ringressi, Marco Brugia, et al.. (2018). Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. Gastroenterology Research and Practice. 2018. 1–14. 15 indexed citations
17.
Lavacchi, Daniele, Stefania Nobili, Marco Brugia, et al.. (2018). A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. BMC Cancer. 18(1). 1024–1024. 3 indexed citations
18.
Nobili, Stefania, Cristina Napoli, Benedetta Puccini, et al.. (2013). Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. Leukemia & lymphoma. 55(9). 2071–2078. 4 indexed citations
19.
Brugia, Marco, et al.. (1996). Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer.. PubMed. 15(5B). 2187–90. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander B. Sibley Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Aurélie Ferru Breakdown of academic impact, for papers by Nikoletta Sidiropoulos Breakdown of academic impact, for papers by In Ae Park Breakdown of academic impact, for papers by Landon C. Brown Breakdown of academic impact, for papers by Khémaies Slimane Breakdown of academic impact, for papers by Meiling Zhu Breakdown of academic impact, for papers by Tristan Maurina Breakdown of academic impact, for papers by Hy-De Lee
Rankless by CCL
2026